Article thumbnail

ATTENUATION OF HALOPERIDOL-INDUCED CATALEPSY BY NORADRENALINE AND L-THREO-DOPS

By WDJ VERHAGENKAMERBEEK, [No Value] HAZEMEIJER, J KORF and JPWF LAKKE

Abstract

In addition to impaired dopaminergic neurotransmission a dysfunctional noradrenergic system has been demonstrated in Parkinson's disease. L-threo-3,4-dihydroxyphenylserine (DOPS), a synthetic precursor of noradrenaline (NA), appears to be effective in the treatment of some akinetic symptoms in parkinsonian patients. In the present study the possible effect of DOPS was studied in rats, in which catalepsy was induced with haloperidol as a model for parkinsonian akinesia. Intravenous infusion of NA (1.5 and 15 mug/kg) or DOPS (2 and 4 mg/kg) in male Wistar rats (240 - 290 g) significantly decreased catalepsy. The effect of DOPS was abolished by pretreatment with the peripheral decarboxylase inhibitor benserazide (2 mg/kg). Pretreatment with Ro 40-7592, a catechol-O-methyltransferase inhibitor, potentiated and prolonged the anticataleptic effect of DOPS. The findings suggest a peripheral site of NA mediated anticataleptic action. Therapy with DOPS may be successful only without a peripheral decarboxylase inhibitor. Moreover, the therapeutic effect of DOPS may be potentiated by COMT inhibition

Topics: NORADRENALINE, L-THREO-3,4-DIHYDROXYPHENYLSERINE (DOPS), CATALEPSY, PARKINSONS DISEASE, COMT INHIBITION, RO 40-7592, PARKINSONS-DISEASE, NOREPINEPHRINE PRECURSOR, STRIATAL DOPAMINE, RAT-BRAIN, METABOLISM, L-THREO-3,4-DIHYDROXYPHENYLSERINE, REVERSAL, STRESS
Year: 1993
DOI identifier: 10.1007/bf02252619
OAI identifier:
Provided by: NARCIS
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://research.rug.nl/en/pub... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles